Your browser doesn't support javascript.
loading
Burden of late effects in a nationwide sample of long-term breast cancer survivors.
Smedsland, Solveig K; Falk, Ragnhild S; Reinertsen, Kristin V; Kiserud, Cecilie E; Brekke, Mette; Bøhn, Synne H; Dahl, Alv A; Vandraas, Kathrine F.
Afiliação
  • Smedsland SK; Department of Oncology, National Advisory Unit for Late Effects After Cancer Treatment, Oslo University Hospital, Oslo, Norway.
  • Falk RS; Department of Community Medicine and Global Health, Institute of Health and Society, University of Oslo, Oslo, Norway.
  • Reinertsen KV; Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway.
  • Kiserud CE; Department of Oncology, National Advisory Unit for Late Effects After Cancer Treatment, Oslo University Hospital, Oslo, Norway.
  • Brekke M; Department of Oncology, National Advisory Unit for Late Effects After Cancer Treatment, Oslo University Hospital, Oslo, Norway.
  • Bøhn SH; General Practice Research Unit, Institute of Health and Society, University of Oslo, Oslo, Norway.
  • Dahl AA; Department of Oncology, National Advisory Unit for Late Effects After Cancer Treatment, Oslo University Hospital, Oslo, Norway.
  • Vandraas KF; Department of Oncology, National Advisory Unit for Late Effects After Cancer Treatment, Oslo University Hospital, Oslo, Norway.
Cancer ; 130(1): 140-149, 2024 01 01.
Article em En | MEDLINE | ID: mdl-37776533
ABSTRACT

BACKGROUND:

Long-term breast cancer survivors (BCSs) may experience several late effects (LEs) simultaneously. This study aimed to identify subgroups of 8-year BCSs with higher burden of LEs who could benefit from closer survivorship care, explore variables associated with higher symptom burden, and describe how symptom burden may affect general functioning.

METHODS:

All Norwegian women aged 20 to 65 years when diagnosed with stage I-III breast cancer in 2011 and 2012 were invited (n = 2803). The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire/BR23, the Fatigue Questionnaire, Assessment of Survivor Concerns, and Scale for Chemotherapy Induced Long-term Neurotoxicity were used to assess 10 common LEs and general functioning. Using latent class analysis, subgroups of BCSs with similar burden of LEs were identified. Multinominal regression analysis were performed to examine variables associated with higher symptom burden.

RESULTS:

The final sample consisted of 1353 BCSs; 46% had low, 37% medium, and 17% high symptom burden. Younger age, short education, axillary dissection, higher systemic treatment burden, higher body mass index, and physical inactivity were associated with higher symptom burden. General functioning scores were lower, and the proportion on disability pension were higher among BCSs in the two most burdened subgroups compared with those in the low burden subgroup.

CONCLUSION:

More than half of long-term BCSs suffered from medium or high symptom burden and experienced impaired general functioning compared with BCS with low symptom burden. Younger age and systemic treatment were important risk factors for higher symptom burden. BCSs at risk of higher symptom burdens should be identified and offered closer and extended survivorship care.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Sobreviventes de Câncer Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Noruega

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Sobreviventes de Câncer Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Noruega